EBIT: Income before interest and taxes.
Candel Therapeutics, Inc. (CADL) had EBIT of $-48.27M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-38.18M |
|
-- |
|
-- |
|
$48.27M |
|
$-48.27M |
|
$10.08M |
|
$-38.18M |
|
$-38.18M |
|
$-38.18M |
|
$-38.18M |
|
$-38.18M |
|
$-38.18M |
|
|
EBIT |
$-48.27M |
$-47.42M |
|
52.96M |
|
52.96M |
|
$-0.72 |
|
$-0.72 |
|
| Balance Sheet Financials | |
$121.39M |
|
$1.64M |
|
$3.81M |
|
$125.19M |
|
$9.00M |
|
$47.13M |
|
$64.28M |
|
$73.27M |
|
$51.92M |
|
$51.92M |
|
$51.92M |
|
54.90M |
|
| Cash Flow Statement Financials | |
$-38.31M |
|
$-0.56M |
|
$56.10M |
|
$102.92M |
|
$120.15M |
|
$17.23M |
|
$3.82M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.49 |
|
-- |
|
-- |
|
0.48 |
|
0.91 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-38.87M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-73.54% |
|
-73.54% |
|
-30.50% |
|
-38.55% |
|
$0.95 |
|
$-0.73 |
|
$-0.72 |
|